Austria targets global drugmaker in abuse case

Austria’s Federal Competition Authority has accused an unnamed drug manufacturer of charging predatory prices for a cancer medicine, so as to dissuade hospitals from switching to rival generic brands.


Get unlimited access to all Global Competition Review content